Kamada Ltd
NASDAQ:KMDA
Kamada Ltd
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Revenue Growth: Kamada reported third quarter revenue of $47 million, up 13% year-on-year, driven by product portfolio diversity and strong performance in several segments.
Profitability: Adjusted EBITDA for the third quarter was $11.7 million, a 34% increase over last year, and net income rose 37% to $5.3 million.
Guidance Reiterated: Management reaffirmed 2025 full-year revenue guidance of $178–182 million and adjusted EBITDA of $40–44 million.
Product Pipeline: The company advanced new clinical studies, including the SHIELD trial for CYTOGAM and a pivotal Phase III trial for inhaled AAT, with interim data expected by year end.
Distribution Expansion: Distribution business, including biosimilars, delivered robust growth and is expected to continue expanding with new product launches.
Plasma Collection: Kamada expanded plasma collection operations, with two Texas centers ramping toward full capacity, and expects further regulatory approvals.
Royalty Income: GLASSIA royalties declined due to a lower rate but are expected to remain above $10 million in 2026, with growth from other products offsetting the impact.
